Home Blog Page 1889

IMG Expands iTravelInsured Choice with New Add-Ons and Specialized Plans

INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ — IMG (International Medical Group) has announced new optional coverage add-ons to its most popular travel insurance plan, iTravelInsured Choice, and the launch of two new products.

Travelers now have the option to expand their iTravelInsured Choice coverage in several key areas through a variety of add-ons at an additional cost:

  • Cancel For Any Reason (CFAR) & Interruption For Any Reason (IFAR) coverage
  • Increased medical coverage
  • Additional benefits and covered reasons specific to cruises
  • Enhanced benefits to accommodate adventurous activities and traveling with sporting equipment

“At IMG, we know travel isn’t one-size-fits-all, and neither is travel insurance,” said Justin Poehler, Chief Commercial Officer at IMG. “With these new add-on options, travelers can easily customize their iTravelInsured Choice plan and choose the coverage that’s best for their trip, whether they want extra medical protection or coverage tailored to adventure sports.”

Building on this flexibility, IMG has also introduced two new products under the iTravelInsured Choice umbrella. iTravelInsured Choice Cruise is a new plan designed specifically for cruise travelers, with additional benefits and covered reasons addressing excessive water levels, port closures, mechanical issues, and more. iTravelInsured Choice Departure is another new product designed for travelers with little to no non-refundable trip expenses, providing primary coverage for medical expenses and key emergency benefits and services.

“With the launch of iTravelInsured Choice Cruise and iTravelInsured Choice Departure, we’re giving travelers more targeted protection based on how and where they travel,” said Grant Hayes, Global Head of Travel at IMG. “Whether you’re setting sail or heading overseas, there is an iTravelInsured Choice plan to meet your trip’s specific needs and provide you with global peace of mind.”

To learn more about IMG’s award-winning travel and health safety solutions, please visit www.imglobal.com.

About IMG® (International Medical Group®)
IMG® (International Medical Group®), a SiriusPoint company, is an award-winning global insurance benefits and assistance services company that has served millions of members worldwide since its founding in 1990. The preeminent provider of travel and health safety solutions, IMG offers a wide range of insurance programs, including international private medical insurance, travel medical insurance, and travel insurance, as well as enterprise services, including insurance administrative services and 24/7 emergency medical, security, and travel assistance. IMG’s world-class services, combined with an extensive product portfolio, provide Global Peace of Mind® for travelers, students, missionaries, marine crews, and other individuals or groups traveling, working, or living away from home. For more information, please visit www.imglobal.com.

Media Contact: Carly Kessler, IMG Communications Manager, carly.kessler@imglobal.com

Securing Global Financial Transactions: ReconArt Achieves 70% Faster Compliance with Armor Defense and Oracle

DALLAS, Oct. 14, 2025 /PRNewswire/ — ReconArt, a leading provider of enterprise-class reconciliation and financial solutions, announced it has selected Armor Defense’s Managed Detection and Response (MDR) services on Oracle Cloud Infrastructure (OCI) to secure its high-performance financial platform.

In financial services, precision and resilience are non-negotiable. A single missed transaction or failed control can trigger financial loss, regulatory action, or lasting reputational damage. Sustaining this precision and resilience demands Armor’s advanced defense – anticipating and neutralizing threats before they disrupt business.

“ReconArt has trusted Armor for over 15 years. This new Armor + OCI solution supports our global customers such as Expedia, Daikin, BMO, and Klar, some processing more than 30 million transactions per day,” said Ivan Popov, CTO of ReconArt. “Armor’s proactive security and compliance expertise – combined with OCI’s performance – gives us the confidence to innovate. We know our platform is secure, compliant, and resilient at scale.”

The new solution provides ReconArt with measurable, strategic advantages:

  • 6X performance capacity, ensuring speed and accuracy at scale.
  • 70% faster time to compliance across regulations and frameworks, including PCI DSS, SOC 2, ISO 27001, GDPR, and DORA.
  • AI-accelerated threat detection and response, powered by Armor’s 24×7 security operations and agentic AI.

ReconArt’s customers – accounting and finance teams operating under relentless regulatory scrutiny – are seeing fewer disruptions, faster audits, and greater trust in their data.

“ReconArt exemplifies how financial organizations can turn compliance and security into a growth advantage,” said Chris Drake, Founder and CEO of Armor Defense. “By integrating Oracle Cloud Guard and Security Zones, we’re helping enterprises protect what matters most – without slowing innovation.”

Powered by Armor’s intelligent security operations and Oracle’s high-performance infrastructure, ReconArt ensures every transaction is trusted, every audit is simplified, and every growth opportunity is secure.

Armor will feature ReconArt and other enterprise success stories at Oracle AI World, October 13 – 16 in Las Vegas. 

About Armor

Armor is a global leader in cloud-native managed detection and response. Trusted by over 1,700 organizations across 40 countries, Armor delivers cybersecurity, compliance consulting, and 24/7 managed defense built for transparency, speed, and results. By combining human expertise with AI-driven precision, Armor safeguards critical environments to outpace evolving threats and build lasting resilience. For more information, visit our website, follow us on LinkedIn, or request a free Cyber Resilience Assessment.

 

True Global Ventures Announces Investment in Prezent AI accompanying Its Acquisition of Prezentium

Prezent AI raises $30 million to acquire Prezentium and redefine enterprise business communication through AI and services integration

SAN FRANCISCO, Oct. 14, 2025 /PRNewswire/ — True Global Ventures (TGV) proudly announces its continued support and participation in Prezent AI’s latest $30 million funding round, accompanying the company’s strategic acquisition of Prezentium, the leading business presentation services firm in Life Sciences.

Rajat Mishra, Founder & CEO of Prezent AI
Rajat Mishra, Founder & CEO of Prezent AI

The round, led by Multiplier Capital and Nomura Strategic Ventures, with participation from True Global Ventures, Greycroft and existing investors, positions Prezent AI company at a $400 million valuation.

A New Category in Enterprise Communication

Prezent AI, founded by Rajat Mishra, is pioneering a new category at the intersection of AI, communication, and enterprise productivity.

Unlike traditional presentation tools or agencies, Prezent AI combines AI-driven automation with human creativity and services, offering Fortune 2000 enterprises a single, scalable platform to accelerate and elevate their business communication.

The acquisition of Prezentium, founded by Deepti Juturu, strengthens this vision. Together, the companies integrate AI technology and human expertise, providing enterprises with a complete “AI + services” solution that delivers outcomes faster, smarter, and more efficiently.

Transforming a $20 Billion Market

With this acquisition and funding, Prezent AI is accelerating its mission to disrupt the $20 billion global agency and consultancy market by creating the first AI + human-augmented business communication platform.

The platform enables organizations to:

  • Transform complex data into business-ready presentations in minutes
  • Create brand-aligned sales and Business Review decks at scale
  • Integrate with enterprise workflows via APIs and presentation agents
  • Build a “Company Presentation Brain” — where communication knowledge compounds over time

Investor Perspective

The combined entity offers corporate clients far greater flexibility in how they approach business communication. They can now rely on a master presentation delivered overnight while achieving measurable productivity gains in how presentations are adapted and deployed across business lines and teams. This unique blend of AI acceleration and human expertise enables enterprises to communicate faster and at scale.” said Frank Desvignes, Founding Partner at True Global Ventures.

A Bold Vision for the Future

Prezent AI is not just about creating slides,” said Rajat Mishra, CEO and Founder of Prezent AI. “Our north star is delivering great business communication outcomes — powered by AI acceleration and human expertise. With Prezentium joining our platform, we’re one step closer to building the complete AI-enabled communication lifecycle for enterprises.

About Prezent AI

Prezent AI is an AI-powered business communication platform that helps enterprise teams create, optimize, and deliver high-impact presentations. Headquartered in Los Altos, California, the company serves global clients across life sciences, technology, and manufacturing, combining AI, software, and expert human services into one integrated system.

Learn more: www.prezent.ai

About True Global Ventures

True Global Ventures (TGV) is a global venture capital firm investing in serial entrepreneurs leading AI and Blockchain companies. With presence across San Francisco, New York, Paris, London, Stockholm, Dubai, Hong Kong and Singapore, TGV backs visionary founders building the next generation of transformative technology ventures.

Learn more: https://www.tgv4plus.com/

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations

SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit’s AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that predict response to immune checkpoint inhibitors (ICIs), offering new potential to guide more effective and personalized cancer treatment.

Among these, the first study, selected for oral presentation, was conducted in collaboration with Chiara Cremolini, MD, PhD, Professor of Medical Oncology at the University of Pisa, Italy. Researchers applied Lunit SCOPE IO to pre-treatment H&E slides from patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) enrolled in the AtezoTRIBE and AVETRIC trials. The AI quantified multiple cell types within the tumor microenvironment, generating a biomarker that stratified patients into “biomarker-high” and “biomarker-low” groups.

In the AtezoTRIBE trial, biomarker-high patients treated with atezolizumab plus FOLFOXIRI/bevacizumab showed significantly improved progression-free survival (PFS) and overall survival (OS) compared to biomarker-low patients, while no such benefit was observed in the control arm. Validation in the AVETRIC cohort confirmed improved survival outcomes for biomarker-high patients receiving ICI-based therapy, with better PFS and OS compared to biomarker-low patients. These results suggest that an AI-derived tumor microenvironment biomarker could help identify patients with pMMR mCRC who are most likely to benefit from immunotherapy combinations—an urgent unmet need in this population.

A collaborative study with Yonsei University College of Medicine, Korea, evaluated whether AI-defined immune phenotypes (IP) could predict outcomes in patients with advanced clear cell renal cell carcinoma (ccRCC) treated with either nivolumab plus ipilimumab (NIVO+IPI) or sunitinib (SUN). Using Lunit SCOPE IO, tumors were classified as inflamed or non-inflamed, based on the density and spatial distribution of tumor-infiltrating lymphocytes.

Patients with inflamed tumors treated with NIVO+IPI demonstrated significantly longer PFS, OS, and higher response rates (60.5% vs. 23.2%) compared to those with non-inflamed tumors. No such benefit was observed in the SUN arm. Findings were validated in an independent ccRCC cohort and aligned with inflamed gene expression signatures from The Cancer Genome Atlas, supporting AI-based immune phenotyping as a promising biomarker to guide treatment selection between immunotherapy combinations and targeted therapies in first-line treatment for ccRCC.

The third study, conducted in collaboration with the National Cancer Center Hospital East (NCCHE) Japan, further validated the predictive power of Lunit SCOPE IO for ICI treatment response in non-small cell lung cancer (NSCLC) patients. In this multicenter prospective study, tumors classified as inflamed showed significantly better responses and longer survival with ICI therapy compared to non-inflamed tumors, a difference not observed among patients treated with cytotoxic chemotherapy. This result strengthens the evidence supporting Lunit SCOPE IO as a predictive biomarker for immunotherapy benefit in NSCLC.

“At ESMO 2025, we are demonstrating how AI can unlock predictive biomarkers directly from routine pathology slides,” said Brandon Suh, CEO of Lunit. “These findings show the potential of Lunit SCOPE IO to help identify patients who will truly benefit from immunotherapy—whether in colorectal or kidney cancer—and to guide treatment strategies that can make cancer care more precise and effective.”

Lunit’s Featured Presentations at ESMO 2025

Visit Lunit at booth #3017 to learn more about its latest AI-powered cancer research and innovations in digital pathology.

###

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit’s FDA-cleared Lunit INSIGHT suite supports cancer screening at over 7,000 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

 

Sankaty Jet Capital Launches to Deliver Lending Solutions for the Underserved Business Aviation Market

STAMFORD, Conn., Oct. 14, 2025 /PRNewswire/ — Sankaty Jet Capital, a new business aviation finance platform, today announced its official launch. Sankaty Jet Capital, a business aviation lending platform, was formed to provide financing solutions for counterparties across the business aviation industry.

Ford von Weise, who will serve as Chief Executive Officer (CEO) of Sankaty Jet Capital, has over 25 years of experience in the business aviation finance industry. Prior to founding Sankaty Jet Capital, Mr. von Weise was Director and Head of Aircraft Finance & Advisory Services at Citi Private Bank, where he provided business aircraft financing solutions to Citi’s individual ultra-high net worth clients and corporate clients globally. Prior to his time at Citi, Mr. von Weise served as Vice President of Business Aviation Finance for Merrill Lynch Capital and GMAC Commercial Finance.

“Sankaty Jet Capital was created to fill a long-standing gap in the business aviation finance marketplace,” said Ford von Weise, CEO of Sankaty Jet Capital. “Sankaty is focused on doing one thing exceptionally well: providing financing solutions to underserved market segments.”

About Sankaty Jet Capital: 
Sankaty Jet Capital is a business aviation lending platform focused on providing financing solutions for counterparties across the business aviation industry.

CONTACT: ford@sankatyjet.com 

India’s No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch ‘Hyundai Hope for Cancer’ to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ — Indian Institute of Technology Madras (IIT Madras), India’s No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch ‘Hyundai Hope for Cancer’ – a pioneering initiative dedicated to transforming paediatric cancer care in India.

The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025
The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025

As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor. This initiative aligns with Hyundai’s global ‘Hope on Wheels’ program, reinforcing its longstanding commitment to supporting children battling cancer worldwide.

At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras. It will also serve as a collaborative hub for clinicians, researchers, pharmaceutical scientists, and global partners, contributing to international efforts such as the International Cancer Genome Consortium (ICGC) and WHO’s International Agency for Research on Cancer (IARC).

The Centre, launched recently, will also focus on genomic sequencing to identify genetic mutations, laying the foundation for a national paediatric cancer genome database and personalized treatment protocols. It features India’s first community-based Cancer Tissue Biobank, enabling advanced genomic research in paediatric leukaemia and lymphoma.

With a total sum of INR 56 Crore committed towards this initiative, HMIF has also established a dedicated INR 3 Crore Cancer Care Fund to ensure equitable access to treatment for economically disadvantaged patients.

The project is being headed by Prof. S. Mahalingam, Department of Biotechnology, IIT Madras.

The Centre will further:

  • Collect and sequence 1,600+ samples for research
  • Provide free treatment to 30-50 children
  • Upskill 100+ technicians in genomics
  • Deploy Mobile Medical Units to expand healthcare access in underserved regions

Sharing a Message for the launch event, Shri. Dharmendra Pradhan, Hon’ble Education Minister, Government of India said, “By building an Indian childhood cancer genomic database, strengthening early detection and screening, and expanding access for underserved communities, the programme exemplifies ‘Sabka Prayas’ in action and reaffirms our commitment to equitable, technology-enabled healthcare. I call upon researchers, clinicians, and innovators across the country to collaborate through this platform to bring hope, precision care and better survival outcomes to every child in need.”

 

India’s No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch ‘Hyundai Hope for Cancer’ to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ — Indian Institute of Technology Madras (IIT Madras), India’s No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch ‘Hyundai Hope for Cancer’ – a pioneering initiative dedicated to transforming paediatric cancer care in India.

The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025
The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025

As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor. This initiative aligns with Hyundai’s global ‘Hope on Wheels’ program, reinforcing its longstanding commitment to supporting children battling cancer worldwide.

At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras. It will also serve as a collaborative hub for clinicians, researchers, pharmaceutical scientists, and global partners, contributing to international efforts such as the International Cancer Genome Consortium (ICGC) and WHO’s International Agency for Research on Cancer (IARC).

The Centre, launched recently, will also focus on genomic sequencing to identify genetic mutations, laying the foundation for a national paediatric cancer genome database and personalized treatment protocols. It features India’s first community-based Cancer Tissue Biobank, enabling advanced genomic research in paediatric leukaemia and lymphoma.

With a total sum of INR 56 Crore committed towards this initiative, HMIF has also established a dedicated INR 3 Crore Cancer Care Fund to ensure equitable access to treatment for economically disadvantaged patients.

The project is being headed by Prof. S. Mahalingam, Department of Biotechnology, IIT Madras.

The Centre will further:

  • Collect and sequence 1,600+ samples for research
  • Provide free treatment to 30-50 children
  • Upskill 100+ technicians in genomics
  • Deploy Mobile Medical Units to expand healthcare access in underserved regions

Sharing a Message for the launch event, Shri. Dharmendra Pradhan, Hon’ble Education Minister, Government of India said, “By building an Indian childhood cancer genomic database, strengthening early detection and screening, and expanding access for underserved communities, the programme exemplifies ‘Sabka Prayas’ in action and reaffirms our commitment to equitable, technology-enabled healthcare. I call upon researchers, clinicians, and innovators across the country to collaborate through this platform to bring hope, precision care and better survival outcomes to every child in need.”

Photo: https://laotiantimes.com/wp-content/uploads/2025/10/iit_madras_hmif-1.jpg
Logo: https://laotiantimes.com/wp-content/uploads/2025/10/iit_madras_logo-1.jpg

Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix’s Biomimetic Collagen Rated “International Leading-Edge”

—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025

CHENGDU, China, Oct. 14, 2025 /PRNewswire/ — The 2025 Chinese Biomaterials Congress recently convened in Shaoxing, Zhejiang, bringing together a prestigious gathering of leading minds in the field. Attendees included Chinese Academy of Engineering academicians Zhang Xingdong and Wang Yingjun, Chinese Academy of Sciences academicians Chen Xuesi, Tang Peifu, and Chen Chunying, alongside renowned international experts such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society and Royal Academy of Engineering Fellow Molly Stevens, Professor Ki Dong Park (Fellow of the Korean Academy of Science and Technology and President of the 2024 World Biomaterials Congress), and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials. The assembly engaged in profound discussions on the frontiers and application prospects of biomaterials.

Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025
Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025

LivingPhoenix Regenerative Technologies Development (Chengdu) Co., Ltd., recognized as the world’s first scientific innovation company exclusively dedicated to the research, development, and translation of triple-helix biomimetic collagen, was invited to the Congress. The company systematically presented its proprietary research achievements in triple-helix biomimetic collagen for the first time, garnering significant attention from attending scholars, experts, and industry representatives.

At the session on Biomimetic and Life-Like Materials, Mr. Qin Xingjiong, Founder of LivingPhoenix® and Committee Member of the Rehabilitation Biomaterials Branch of the Chinese Society for Biomaterials, delivered an academic report titled “Safety and Efficacy Evaluation of a Chemically Synthesized Triple-Helix Biomimetic Collagen and Latest Research Progress.” The report detailed research collaboratively completed by his team with Beijing Hospital, Peking University Third Hospital, the Ninth People’s Hospital of Shanghai Jiao Tong University School of Medicine, and The University of Tokyo, among other institutions. The study, with Professor Zhao Hongyi of Beijing Hospital and Professor Dong Jiying of Shanghai Ninth People’s Hospital serving as corresponding authors, featured Dr. Zhang Xinling of Beijing Hospital as the first author and Dr. Li Kexin of The University of Tokyo as a co-first author. Contributors included Lu Nan, Dr. Takafumi Takebayashi, Dr. Zhou Boyu, and Xie Hongbin. The related peer-reviewed paper was published in the SCI Q1 journal Frontiers in Bioengineering and Biotechnology in April 2025. The paper concluded that the biomimetic collagen component is safe, structurally stable, thermally stable, and demonstrates good biocompatibility and functionality in both in vitro and in vivo experiments, with significant potential for promotion and application in regenerative biomedicine.

This achievement originates from fundamental research initiated in 2001 by Professor Masao Tanihara, Doctor of Engineering from Kyoto University, Japan. Developed in collaboration with the Nara Institute of Science and Technology, Kyoto University Faculty of Medicine, Kyoto Prefectural University of Medicine, and Nagoya University Graduate School, among others, the initial technological system was formed over a decade, receiving national-level support from Japanese programs including the “Knowledge Cluster Initiative” and “University Venture Creation Project.” In 2023, Dr. Takafumi Takebayashi, holder of the first-generation technology, joined LivingPhoenix® with the relevant intellectual property. The company concurrently established a core R&D team led by Dr. Zhou Boyu of The University of Tokyo, fostering continuous iteration and innovation through collaboration with Peking University, the Chinese Academy of Sciences, Shanghai Jiao Tong University, Naval Medical University, the University of Science and Technology of China, and the Tianfu Jincheng Laboratory (Frontier Medical Center). This effort achieved technological upgrades from version 1.0 to 2.0, resulting in the grant of several invention patents and the filing of multiple PCT international patent applications.

According to an assessment by Dr. Zheng Yongli, a Patent Attorney at Chengdu Gaoyuan Intellectual Property Agency, a search and analysis of 240 global peer patents and their technical solutions confirmed that the Biomimetic Collagen Technology version 1.0 is globally pioneering and internationally leading. Its version 2.0 further enhances stability and self-assembly characteristics through the “Polymerization-Induced Self-Assembly (PISA) in water” process. Notably, it represents the world’s first visualization of collagen fibrils using 300 kV Cryo-Transmission Electron Microscopy to capture the ultrastructure of “collagen fibrils,” verifying the repeatability and consistency of self-assembled morphological features across multiple production batches, thus also possessing a “globally pioneering and internationally leading” attribute.

The product currently boasts a stable triple-helix structure and collagen fibrils, effectively addressing issues common in commercially available collagen products, such as short duration of effect and suboptimal biological functionality. It also demonstrates a cost-leading advantage in its synthesis process. Amid national policies encouraging the development of domestically pioneered, internationally leading high-end medical devices, related achievements have successfully completed registration with the NMPA’s Medical Device Master File and filing as a cosmetic ingredient. Among these, the injectable biomimetic collagen lyophilized fiber has passed the classification review as a Class III medical device. Subsequent product lines suitable for functional cosmetics, medical dressings, fillers/implants, tissue engineering, and other application scenarios are slated for gradual release.

For collaboration opportunities in cosmetics, medical aesthetics, or high-end biomaterials, contact:
Email:POGMENT@mylivingphoenix.com
Official website:www.mylivingphoenix.com